Lead sponsor
Janssen Pharmaceutica N.V., Belgium
3 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
3
Trials led
1
Ongoing
819
Total enrollment
81
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
1
Phase 3
2
Trials by status
Active, not recruiting
1
Completed
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled StudyAlzheimer's diseasePh 3Completed415
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With DementiaMultiple dementia etiologiesPh 3Completed349